LCAR-T2C CAR-T cell therapy (Nanjing Medical University)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameLCAR-T2C CAR-T cell therapy (Nanjing Medical University)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD4

TargetsT-cell surface antigen CD4

Therapy Area/IndicationsLymphoma, T-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaDiscontinued

Originator CompaniesThe First Affiliated Hospital With Nanjing Medical University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesThe First Affiliated Hospital With Nanjing Medical University

Active IndicationsN/A

Inactive IndicationsLymphoma, T-Cell

Other Information

ATC CodeN/A